Mubadala Secures Stake in UCB’s Chinese Neurology, Allergy Business

Abu Dhabi’s Mubadala Investment Company, in partnership with Singapore-based CBC Group, has finalized a $680 million acquisition of the Chinese neurology and allergy business of Belgian pharmaceutical giant UCB. This strategic move strengthens Mubadala’s presence in the Chinese healthcare sector, a market with significant growth potential.

The deal encompasses UCB’s neurology products, including Keppra, Vimpat, and Neupro, along with its allergy medications, Zyrtec and Xyzal, in mainland China. Additionally, it includes UCB’s manufacturing facility in Zhuhai, a key asset for local production. Together, these products generated approximately €131 million ($146.5 million) in sales within China in 2023.

Mubadala’s head of China, Mohamed Albadr, emphasized that this acquisition aligns with the company’s long-term strategy to expand its healthcare investments in Asia, particularly in sectors with robust growth potential. The investment is expected to enhance UCB’s capacity to deliver innovative treatments in the region, benefiting from Mubadala’s financial backing and strategic expertise.

The transaction, currently awaiting regulatory approvals, is anticipated to be finalized by the fourth quarter of 2024. PJT Partners served as the financial advisor to Mubadala and CBC Group, while Clifford Chance provided legal counsel.

This move is part of Mubadala’s broader strategy to diversify its portfolio, particularly in the biotechnology and pharmaceutical sectors, where it has been increasingly active. The company has shown a strong commitment to expanding its influence in global healthcare, with recent investments spanning biotechnology firms and other healthcare-related ventures. The collaboration with CBC Group underscores the strategic importance of the Chinese market and highlights Mubadala’s continued focus on sectors poised for substantial growth.

As the deal progresses, it will likely influence the dynamics of the Chinese pharmaceutical industry, particularly in neurology and allergy treatments, where UCB’s products have already established a strong foothold. The integration of these assets into Mubadala’s portfolio could pave the way for future expansions and partnerships in the region, further solidifying its position as a key player in the global healthcare market.